Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Wechsler

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Medical Device Technology|July 11, 2003
Woven fabrics: recent developments and future applicationsThomas Wechsler
Medical Device Technology|July 16, 2002
Filters and open-heart surgeryThomas Wechsler
Nature|March 15, 2011
Aberrant chromosome morphology in human cells defective for Holliday junction resolutionThomas Wechsler, Scott Newman, Stephen C West
Molecular Therapy. Methods & Clinical Development|November 2, 2022
AAV9-NGLY1 gene replacement therapy improves phenotypic and biomarker endpoints in a rat model of NGLY1 DeficiencyLei Zhu, Brandon Tan, Selina S Dwight, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2004
DNA-PKcs function regulated specifically by protein phosphatase 5Thomas Wechsler, Benjamin P C Chen, Ryan Harper, et al.
Journal of Biochemistry|October 26, 2021
GlcNAc-Asn is a biomarker for NGLY1 deficiencyWilliam F Mueller, Lei Zhu, Brandon Tan, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 29, 2021
ZFN-mediated in vivo gene editing in hepatocytes leads to supraphysiologic α-Gal A activity and effective substrate reduction in Fabry miceSilvere Pagant, Marshall W Huston, Luciana Moreira, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 18, 2007
RIDDLE immunodeficiency syndrome is linked to defects in 53BP1-mediated DNA damage signalingGrant S Stewart, Tatjana Stankovic, Philip J Byrd, et al.
Molecular Therapy. Methods & Clinical Development|August 11, 2020
AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate ReductionMakiko Yasuda, Marshall W Huston, Silvere Pagant, et al.
Blood|August 23, 2015
In vivo genome editing of the albumin locus as a platform for protein replacement therapyRajiv Sharma, Xavier M Anguela, Yannick Doyon, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Medical Device Technology|July 11, 2003
Woven fabrics: recent developments and future applicationsThomas Wechsler
Medical Device Technology|July 16, 2002
Filters and open-heart surgeryThomas Wechsler
Nature|March 15, 2011
Aberrant chromosome morphology in human cells defective for Holliday junction resolutionThomas Wechsler, Scott Newman, Stephen C West
Molecular Therapy. Methods & Clinical Development|November 2, 2022
AAV9-NGLY1 gene replacement therapy improves phenotypic and biomarker endpoints in a rat model of NGLY1 DeficiencyLei Zhu, Brandon Tan, Selina S Dwight, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2004
DNA-PKcs function regulated specifically by protein phosphatase 5Thomas Wechsler, Benjamin P C Chen, Ryan Harper, et al.
Journal of Biochemistry|October 26, 2021
GlcNAc-Asn is a biomarker for NGLY1 deficiencyWilliam F Mueller, Lei Zhu, Brandon Tan, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 29, 2021
ZFN-mediated in vivo gene editing in hepatocytes leads to supraphysiologic α-Gal A activity and effective substrate reduction in Fabry miceSilvere Pagant, Marshall W Huston, Luciana Moreira, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 18, 2007
RIDDLE immunodeficiency syndrome is linked to defects in 53BP1-mediated DNA damage signalingGrant S Stewart, Tatjana Stankovic, Philip J Byrd, et al.
Molecular Therapy. Methods & Clinical Development|August 11, 2020
AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate ReductionMakiko Yasuda, Marshall W Huston, Silvere Pagant, et al.
Blood|August 23, 2015
In vivo genome editing of the albumin locus as a platform for protein replacement therapyRajiv Sharma, Xavier M Anguela, Yannick Doyon, et al.
Pageof 2